Context: A growing body of evidence suggests that endocrine disrupting compounds (EDCs) contribute to female reproductive disorders. Objective: To calculate the associated combined health care and economic costs attributable to specific EDC exposures within the European Union (EU). Design: An expert panel evaluated evidence for probability of causation using the Intergovernmental Panel on Climate Change weight-of-evidence characterization. Exposure-response relationships and reference levels were evaluated, and biomarker data was organized from carefully identified studies from the peer-reviewed literature to represent European exposure and approximate burden of disease as it occurred in 2010. Cost-of-illness estimation utilized multiple peer-reviewed sources. Setting, Patients and Participants and Intervention: Cost estimation was carried out from a societal perspective, i.e. including direct costs (e.g. treatment costs) and indirect costs such as productivity loss. Results: The most robust EDC-related data for female reproductive disorders exists for (a) DDE-attributable fibroids and (b) phthalate-attributable endometriosis in Europe. In both cases the strength of epidemiological evidence was rated as low and the toxicological evidence as moderate, with an assigned probability of causation of 20-39%. Across the EU, attributable cases were estimated to be 56,700 and 145,000 women, respectively, with total combined economic and health care costs potentially reaching €163 million and €1.25 billion. Conclusions: EDCs (DDE and phthalates) may contribute substantially to the most common reproductive disorders in women, endometriosis and fibroids, costing nearly €1.5 billion annually. These estimates represent only EDCs for which there were sufficient epidemiologic studies and those with the highest probability of causation. These public health costs should be considered as the EU contemplates regulatory action on EDCs.
to the cost burden of the chosen disease end points in the EU. This approach was interesting and eye-opening. Although I had few disagreements with the choice of papers, the reason for focusing on the chosen studies, or the resources that were used to assess the cost of disease burden, the paper suffered in the clarity in Methods and Results sections. It is not clear if the authors just needed to go over the paper once more or if apples and oranges were being compared.
Suggested changes: IntroductionYou may want to consider changing the phrase "DES experience". Something like "human prenatal DES exposure paradigm" might be a little more descriptive?
We have revised as suggested.
It seems that some important description of DES effects are missing… animals and humans share similar malformations of the female repro tract following prenatal DES exposures and the DESderived clear cell tumors in women were not mentioned as affecting the female repro tract.
We find this comment puzzling because clear cell adenocarcinoma is mentioned at the onset of the DES section.
MethodsIn organizing this section, is it possible to talk about one disease outcome and then the other? I understand why you did it the way it is in the present manuscript, but it really bounced around and it moving realted sections together would help focus on the outcome.
We followed the structure of previous papers. We do sympathize with the reviewer's concern but have not made further changes.
In the data that was used from the DEMOCOPHES study, I feel the need to know if this was data from urine (more appropriate than blood) and was there anything unusual about the women in this study (infertile, etc)??
DEMOCOPHES measurements were in urine and in a general population (now explicated).
I would like to know more about how sure we should be in the choice of data without having to go read the entire paper. We do not have information on other papers that were considered in these circumstances, so should have some detail on the "best" paper.
Supplemental tables providing brief information on all papers providing information on exposure associations for leiomyoma and endometriosis are included in this revision.
In the modeling DDE-fibroids section, "Women in the EU…. "is too vague. Which women? Where is this information coming from? There is no reference. Govarts et al . 57 In the same paragraph, for reference 59, give the number of women in the cohort (vs "large cohort").
This is clarified as follows: "Women in the EU between the ages of 15 and 54 years in the year 2010 were assumed to have a distribution of DDE levels corresponding to those identified by

This has been added -thank you.
Same paragraph, more detail is needed for how incidence rates were "obtained". This sentence is not clear.
We have clarified further.
Additionally, when you talk about applying these rates to the number of women, it is not clear that you have 5 year groupings from the database referenced (#60).
The reference cited has 5-year population data across the lifespan. These were summed as appropriate to generate the relevant population data.
Results -
The results section seems to need another going over. At the end of the first paragraph on pg 14, the conclusions sentence is misplaced. The header of the next paragraph is wrong, I believe, and the conclusion statement of the first paragraph on page 15 should say POPS maybe, but instead says phthalates -the paragraph was all about TCDD and PCBs -and this is confusing as I thought it would be about phthalates. This is the only major issue -it was hard to follow all the different chemicals discussed when I thought this would be about DDE and fibroids only and phthalates and endometriosis. Your tables very clearly state DDE and fibroids and Phthalates and endometriosis -results section does NOT match this.
We regret the error, which is now corrected.
In the first paragraph of the results, please indicate how many studies were considered.
The revision addresses this issue through citation.In the second paragraph, first sentence, please be clear on which end point these studies were chosen.We have clarified as requested.
In the bottom paragraph on pg 15, the seven references should be provided in the text -it helps to provide those authors with information on whether or not their papers thought to be some of the best, as you then clarify why you chose the one paper in the end. It should help them design better studies in the future… This long paragraph, which extends to most of page 16, contains no references and should have several. Please add in the needed references.
In response to these comments we have created two supplemental tables that summarize the human studies considered in this analysis. Because the experimental evidence is extensive, a similar summary is not possible and we have simply referenced the most relevant references in the text.
The second paragraph on page 16 is not clear enough. Where did the values listed come from?
We have identified the sample size, and clarified data source for phthalate values.
There is not enough explanation. What is the age group of the women, again?
We have clarified the age range as requested.
DiscussionYou say the "…..exclusion of fetal and peri-conceptional exposures…" in the first paragraph on pg 18, when in fact you didn't exclude the data, there just isn't any. This needs to be clear.
Thank you --revised as requested.
In the second paragraph on pg 19, you again refer to only DDE and phthalate as the focus of this assessment. Very confusing based on the comments I provided above -results section does not agree with this. Also, Table 1 Although a growing body of evidence exists supporting supports the ODS conceptual paradigm and the vulnerability of the developing ovary to the actions of endocrine disrupting chemicals (26) , characterizing the effects of exposures on the developing ovary remains a formidable research challenge. In part, this can be attributed to the "hidden" data problem, the inability to observe early reproductive endpoints in females relative to males without invasive procedures.
Such "hidden" endpoints include some of the earliest gene and sperm related contributions to the developing embryo, all of which occur prior to implantation. These early endpoints are well Furthermore, the rising incidences of endometriosis and fibroids with age(46) increases the risk of comorbidity, which will multiply the cost burdens of the diseases.
The Endocrine Society recently released its second Scientific Statement on endocrine disrupting chemicals or EDCs. (47) This document reviews the mechanistic, experimental, and epidemiological evidence for the role of endocrine disrupting chemicals in the genesis and progression of obesity and diabetes, female and male reproductive disorders, hormone-sensitive cancers in females, prostate cancer, and developmental and functional disorders of the thyroid and neuroendocrine systems. Importantly, the mode of action of EDCs in the body is varied, complex, and dependent upon both the tissue and developmental stage of exposure (e.g., see Table 2 ; ref (47)). Nevertheless, as summarized in the Endocrine Society statement, evidence for effects of a host of EDCs, including bisphenol A (BPA), phthalates, pesticides, and persistent organic pollutants (POPs) on the developing ovary and reproductive tract is growing into a compelling body of evidence.
The prevention of EDC exposures has the potential to minimize the onset and progression of female reproductive diseases in the EU, and the resultant reduction in associated health care and other social costs could have major economic implications. Thus, cost information is essential in the context of regulatory decisions. We therefore extended previous estimates of societal cost (48) (49) (50) (51) , examining the probability of causation of female reproductive conditions for endocrine disrupting chemicals, and quantifying the potential associated costs and burden of disease.
Prevention of EDC exposures minimize the onset of female reproductive diseases in the EU, reducing associated health care and other social costs. In the context of the ongoing regulatory process in the EU, we therefore examined the probability of causation of female reproductive conditions for endocrine disrupting chemicals, and quantified the potential burden of disease and associated costs.
Methods
The expert panel focused on two exposure-outcome relationships: adult diphenyldichloroethene (DDE) exposure with fibroids and adult phthalate exposure with endometriosis. The expert panel considered dioxins, polychlorinated biphenyls and other persistent pollutants, but following the approach of other manuscripts in this series, (48-55) the panel chose not to examine these chemicals because they are already regulated under the Stockholm Convention.
The panel selected these exposure-outcome relationships because of the availability of wellconducted observational human studies to assess effects of these EDCs on female reproductive disorders. The panel recognized that substantial laboratory studies suggest effects of earlier female reproductive tract perturbations as a result of developmental exposures in animal(56), but noted an absence of longitudinal studies to assess such effects in humans. We adhered to the approach described in the accompanying overarching manuscript in evaluating strength of the epidemiological (using the WHO GRADE Working Group criteria)(57, 58) and toxicological literature (using criteria consistent with that proposed in the European Union roadmap for evaluating endocrine disruptors) (59, 60) , and to assigning probability of causation (adapting the
Intergovernmental Panel on Climate Change criteria).(61)
Modeling DDE Exposures among Adult Females in the EU
We utilized data pooled from twelve European birth cohorts by Govarts 
Results
Persistent Organic Pollutant-Attributable Fibroids
The panel considered the evidence supporting a role for both a predisposing effect of developmental exposures as well as an effect of adult exposures on the development of fibroids.
In rodents, DES exposure during fetal development induces alterations to the developing reproductive tract that are remarkably similar to those reported in DES daughters. (71) Importantly, rodent models also provide evidence that developmental exposures to other EDCs Together, the epidemiological and toxicological evaluations resulted in the expert panel endorsing a 20-39% probability of causation of endometriosis fibroids by phthalatesDDE.
Applying the odds ratio (OR) from the Trabert et al 2014 study to DDE biomarker data from twelve countries in the EU and using the 10 th percentile as a reference level, results in OR estimates for fibroids of 1.11-1.51. Applying this to a 2.227/1,000 annual incidence rate, incremental prevalence in the EU attributable to DDE ranges between 2.45/10,000 to 1.15/1,000
for the most highly exposed quantiles of the population (Table 1) . Thus in 2010, an estimated 56,700 women underwent interventions for myoma requiring surgical attention attributable to adult DDE exposures. These cases cost €163 million.
Persistent Organic Pollutant-Attributable Endometriosis
The These evaluations resulted in the expert panel endorsing a 20-39% probability of causation of endometriosis by phthalates.
To estimate attributable disease burden, the panel utilized a large cohort study (n=495) that identified a dose-response relationship between urinary phthalate measurements obtained contemporaneously with the diagnosis of endometriosis. (66) Applying an odds ratio of 1.35 per log unit increase in total phthalates to European urinary total phthalate measurements from DEMOCOPHES (Table 2) , the incremental incidence attributable to phthalates ranged from 1.21/1,000 to 2.82/1,000. In total, this analysis suggests that 145,000 cases of endometriosis among 20-44 year old women, with associated costs of €1.25 billion in 2010, were attributable to phthalates.
Discussion
The main finding of our study is that EDC exposure may contribute to causation of fibroids and 
